|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
EP0983303B1
(en)
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US7312318B2
(en)
*
|
2002-03-01 |
2007-12-25 |
Immunomedics, Inc. |
Internalizing anti-CD74 antibodies and methods of use
|
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
|
CA2473144C
(en)
|
2002-02-05 |
2013-05-28 |
Genentech, Inc. |
Protein purification
|
|
ZA200503075B
(en)
|
2002-11-07 |
2006-09-27 |
Immunogen Inc |
Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
|
|
CA2512000C
(en)
|
2002-12-26 |
2011-08-09 |
Eisai Co., Ltd. |
Selective estrogen receptor modulator
|
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
|
PE20110220A1
(es)
|
2006-08-02 |
2011-04-11 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
EP2711018A1
(en)
|
2009-06-22 |
2014-03-26 |
MedImmune, LLC |
Engineered Fc regions for site-specific conjugation
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
RS56042B1
(sr)
|
2010-06-10 |
2017-09-29 |
Seragon Pharmaceuticals Inc |
Modulatori estrogenih receptora i njihove upotrebe
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
KR101972446B1
(ko)
|
2011-05-27 |
2019-04-25 |
글락소 그룹 리미티드 |
Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질
|
|
FR2986002B1
(fr)
|
2012-01-24 |
2014-02-21 |
Servier Lab |
Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
EP2855520B1
(en)
|
2012-06-04 |
2018-09-26 |
Novartis AG |
Site-specific labeling methods and molecules produced thereby
|
|
US20140069822A1
(en)
|
2012-09-10 |
2014-03-13 |
Antec Leyden B.V. |
Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
|
|
ES2732574T3
(es)
|
2012-11-30 |
2019-11-25 |
Novartis Ag |
Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
|
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
EP2953976B1
(en)
|
2013-02-08 |
2021-03-24 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
|
ES2671516T3
(es)
|
2013-02-19 |
2018-06-06 |
Novartis Ag |
Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
|
|
US9498532B2
(en)
*
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
ES2701051T3
(es)
*
|
2013-03-15 |
2019-02-20 |
Novartis Ag |
Conjugados de anticuerpo-fármaco
|
|
FR3008975A1
(fr)
|
2013-07-23 |
2015-01-30 |
Servier Lab |
Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
WO2015095227A2
(en)
*
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
|
FR3015483B1
(fr)
*
|
2013-12-23 |
2016-01-01 |
Servier Lab |
Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
JP2017509337A
(ja)
|
2014-03-12 |
2017-04-06 |
ノバルティス アーゲー |
イムノコンジュゲートを作製する抗体を修飾するための特定部位
|
|
SG11201607339VA
(en)
|
2014-03-13 |
2016-10-28 |
Hoffmann La Roche |
Methods and compositions for modulating estrogen receptor mutants
|
|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
|
TW201625692A
(zh)
*
|
2014-11-14 |
2016-07-16 |
諾華公司 |
抗體藥物結合物
|
|
CN111620861A
(zh)
|
2014-12-09 |
2020-09-04 |
艾伯维公司 |
具有低细胞渗透性的bcl-xl抑制性化合物以及包括它的抗体药物缀合物
|
|
CN113209306A
(zh)
|
2014-12-09 |
2021-08-06 |
艾伯维公司 |
具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物
|
|
CN107207553A
(zh)
|
2014-12-09 |
2017-09-26 |
艾伯维公司 |
Bcl‑xl抑制性化合物和包括其的抗体药物缀合物
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
FR3037958B1
(fr)
|
2015-06-23 |
2019-01-25 |
Les Laboratoires Servier |
Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
FR3037959B1
(fr)
|
2015-06-23 |
2017-08-04 |
Servier Lab |
Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
FR3037956B1
(fr)
|
2015-06-23 |
2017-08-04 |
Servier Lab |
Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
FR3037957B1
(fr)
|
2015-06-23 |
2019-01-25 |
Les Laboratoires Servier |
Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
EP3165536A1
(en)
*
|
2015-11-09 |
2017-05-10 |
Ludwig-Maximilians-Universität München |
Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition
|
|
FR3046792B1
(fr)
*
|
2016-01-19 |
2018-02-02 |
Les Laboratoires Servier |
Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US11306107B2
(en)
|
2016-02-25 |
2022-04-19 |
Amgen Inc. |
Compounds that inhibit MCL-1 protein
|
|
ES2791319T3
(es)
|
2016-04-22 |
2020-11-03 |
Astrazeneca Ab |
Inhibidores de MCL1 macrocíclicos para tratar el cáncer
|
|
BR112018075639A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
conjugados de anticorpo fármaco anti-egfr
|
|
WO2017214462A2
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
AU2017279550A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-B7-H3 antibodies and antibody drug conjugates
|
|
AU2017277534A1
(en)
|
2016-06-08 |
2019-01-03 |
Abbvie Inc. |
Anti-EGFR antibody drug conjugates
|
|
RU2018147224A
(ru)
|
2016-06-08 |
2020-07-14 |
Эббви Инк. |
Конъюгаты антитела к egfr и лекарственного средства
|
|
JP2019524651A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗ｃｄ９８抗体及び抗体薬物コンジュゲート
|
|
MX2018015285A
(es)
|
2016-06-08 |
2019-09-18 |
Abbvie Inc |
Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
|
|
US20200147235A1
(en)
|
2016-06-08 |
2020-05-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
WO2017214322A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
|
RU2019114863A
(ru)
*
|
2016-11-02 |
2020-12-03 |
Иммуноджен, Инк. |
Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp
|
|
CA3043277A1
(en)
|
2016-11-11 |
2018-05-17 |
The Regents Of The University Of California |
Anti-cd46 antibodies and methods of use
|
|
WO2018098534A1
(en)
*
|
2016-12-02 |
2018-06-07 |
Garvan Institute Of Medical Research |
Methods of treating cancer and reagents thereof
|
|
CN110461361A
(zh)
*
|
2017-02-10 |
2019-11-15 |
蜻蜓治疗公司 |
结合bcma、nkg2d和cd16的蛋白
|
|
JP6453507B2
(ja)
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Ｍｃｌ−１タンパク質を阻害する化合物
|
|
WO2018192407A1
(zh)
*
|
2017-04-19 |
2018-10-25 |
四川科伦博泰生物医药股份有限公司 |
细胞毒素和偶联物、其用途和制备方法
|
|
AR113224A1
(es)
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
|
MA51447A
(fr)
*
|
2017-08-01 |
2020-06-10 |
Medimmune Llc |
Conjugué anticorps monoclonal-médicament dirigé contre bcma
|
|
AU2018317828A1
(en)
|
2017-08-15 |
2020-04-02 |
AbbVie Deutschland GmbH & Co. KG |
Macrocyclic MCL-1 inhibitors and methods of use
|
|
US10676485B2
(en)
|
2017-08-15 |
2020-06-09 |
Abbvie Inc. |
Macrocyclic MCL-1 inhibitors and methods of use
|
|
TW201920193A
(zh)
|
2017-08-15 |
2019-06-01 |
美商艾伯維有限公司 |
大環ｍｅｌ-１抑制劑以及使用方法
|
|
US20190160089A1
(en)
*
|
2017-10-31 |
2019-05-30 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
|
MX2020012674A
(es)
*
|
2018-05-29 |
2021-02-09 |
Bristol Myers Squibb Co |
Porciones autoinmolantes modificadas para usarse en profarmacos y conjugados y metodos de uso y fabricacion.
|
|
EP3807644A4
(en)
*
|
2018-06-12 |
2022-07-06 |
Angiex, Inc. |
ANTIBODY-OLIGONUCLEOTIDE CONJUGATES
|